Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease. Five-Year Prospective Results From the Bruneck Study

Journal of the American College of Cardiology

Volumn 47, Issue 11, 2006, Pages 2219-2228

  Tsimikas, Sotirios ^a   Kiechl, Stefan ^d   Willeit, Johann ^d   Mayr, Manuel ^b,c   Miller, Elizabeth R ^a   Kronenberg, Florian ^d   Xu, Qingbo ^b,c   Bergmark, Claes ^e   Weger, Siegfried ^f   Oberhollenzer, Friedrich ^f   Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f BRUNECK HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; LIPOPROTEIN A; PHOSPHOLIPID DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FEMORAL ARTERY; HUMAN; KRINGLE DOMAIN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; ULTRASOUND;

AGED; AGING; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; FEMALE; FEMORAL ARTERY; HUMANS; INFLAMMATION MEDIATORS; INTRACRANIAL ARTERIOSCLEROSIS; LIPOPROTEIN(A); MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHENOTYPE; PHOSPHOLIPIDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 33646902155     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.03.001     Document Type: Article

References (36)

1. Tsimikas S., Glass C., Steinberg D., and Witztum J.L. Lipoproteins, lipoprotein oxidation and atherogenesis. Molecular basis of cardiovascular disease. In: Chien K.R. (Ed). A Companion to Braunwald's Heart Disease (2004), W.B. Saunders Co, Philadelphia, PA 385-413
2. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
3. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
4. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
5. Tsimikas S., Bergmark C., Beyer R.W., et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 360-370
6. Tsimikas S., Lau H.K., Han K.R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein (a). short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109 (2004) 3164-3170
7. Silaste M.L., Rantala M., Alfthan G., et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein (a). Arterioscler Thromb Vasc Biol 24 (2004) 498-503
8. Edelstein C., Pfaffinger D., Hinman J., et al. Lysine-phosphatidylcholine adducts in Kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein (a). J Biol Chem 278 (2003) 52841-52847
9. Kiechl S., Willeit J., Rungger G., Egger G., and Oberhollenzer F. Quantitative assessment of carotid atherosclerosis in a healthy population. Neuroepidemiology 13 (1994) 314-317
10. Kiechl S., and Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 19 (1999) 1484-1490
11. Kiechl S., and Willeit J. The natural course of atherosclerosis. Part II: vascular remodeling. Bruneck Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 1491-1498
12. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 (2002) 185-192
13. Willeit J., Kiechl S., Oberhollenzer F., et al. Distinct risk profiles of early and advanced atherosclerosis. prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 20 (2000) 529-537
14. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein (a) and apolipoprotein(a) phenotype in atherogenesis. prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160
15. Hörkkö S., Bird D.A., Miller E., et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103 (1999) 117-128
16. Friedman P., Hörkkö S., Steinberg D., Witztum J.L., and Dennis E.A. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. importance of Schiff base formation and Aldol condensation. J Biol Chem 277 (2001) 7010-7020
17. Willeit J., and Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis. A population-based study. Arterioscler Thromb 13 (1993) 661-668
18. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
19. Utermann G. Genetic architecture and evolution of the lipoprotein (a) trait. Curr Opin Lipidol 10 (1999) 133-141
20. Rodenburg J., Vissers M.N., Wiegman A., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings. the effect of pravastatin. J Am Coll Cardiol 47 (2006) 1803-1810
21. Willeit J., Kiechl S., Santer P., et al. Lipoprotein (a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck study. Stroke 26 (1995) 1582-1587
22. Palinski W., Hörkkö S., Miller E., et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98 (1996) 800-814
23. Gillotte-Taylor K., Boullier A., Witztum J.L., Steinberg D., and Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 42 (2001) 1474-1482
24. Shaw P.X., Hörkkö S., Chang M.K., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105 (2000) 1731-1740
25. Chang M.K., Binder C.J., Torzewski M., and Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand. phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99 (2002) 13043-13048
26. Boullier A., Gillotte K.L., Hörkkö S., et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 275 (2000) 9163-9169
27. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation. molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 (2003) 736-743
28. Wu R., de Faire U., Lemne C., Witztum J.L., and Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33 (1999) 53-59
29. Hulthe J., Bokemark L., and Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21 (2001) 101-107
30. Karvonen J., Paivansalo M., Kesaniemi Y.A., and Hörkkö S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 (2003) 2107-2112
31. Bergmark C., Tsimikas S., and Witztum J.L. A possible novel function for lipoprotein (a) as a carrier of oxidized phospholipids. Arterioscler Thromb Vasc Biol 25 (2004) e71
32. Danesh J., Collins R., and Peto R. Lipoprotein (a) and coronary artery disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
33. Kronenberg F., Neyer U., Lhotta K., et al. The low molecular weight apo (a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients. a prospective follow-up. J Am Soc Nephrol 10 (1999) 1027-1036
34. Binder C.J., Shaw P.X., Chang M.K., et al. The role of natural antibodies in atherogenesis. J Lipid Res 46 (2006) 1353-1363
35. Blencowe C., Hermetter A., Kostner G.M., and Deigner H.P. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 270 (1995) 31151-31157
36. Karabina S.A., Liapikos T.A., Grekas G., Goudevenos J., and Tselepis A.D. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1213 (1994) 34-38